Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice
- PMID: 16899620
- DOI: 10.1158/1078-0432.CCR-06-0346
Synergistic antitumor activity of taxol and immunotoxin SS1P in tumor-bearing mice
Abstract
Purpose: To investigate the combined antitumor activity in mice of immunotoxin SS1P and Taxol.
Methods: Immunodeficient mice were implanted with A431/K5 tumors expressing mesothelin. Established tumors were treated i.v. with immunotoxin SS1P alone, i.p. with Taxol alone, or with the two agents together. SS1P was radiolabeled with (111)In and used to study the effect of Taxol on its uptake by A431/K5 tumors.
Results: Using doses at which either agent alone caused stabilization of tumor growth, the combination was synergistic causing long-lasting complete remissions in many animals. In contrast, synergy was not observed when the same cells were treated with these agents in vitro. Tumor uptake of (111)In-SS1P was not affected by treatment with Taxol.
Conclusion: The combination of Taxol and SS1P exerts a synergistic antitumor effect in animals but not in cell culture. This effect is not secondary to increased tumor uptake of the immunotoxin. Synergy could be due to improved immunotoxin distribution within the tumor or could involve factors released by other cell types in the tumors.
Similar articles
-
Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.Clin Cancer Res. 2007 Dec 1;13(23):7166-71. doi: 10.1158/1078-0432.CCR-07-1592. Clin Cancer Res. 2007. PMID: 18056197
-
Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors.Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17099-104. doi: 10.1073/pnas.0708101104. Epub 2007 Oct 16. Proc Natl Acad Sci U S A. 2007. PMID: 17940013 Free PMC article.
-
Tumor-directed radiation and the immunotoxin SS1P in the treatment of mesothelin-expressing tumor xenografts.Clin Cancer Res. 2006 Aug 15;12(16):4983-8. doi: 10.1158/1078-0432.CCR-06-0441. Clin Cancer Res. 2006. PMID: 16914588
-
Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3444-51. doi: 10.1158/1078-0432.CCR-05-2823. Clin Cancer Res. 2006. PMID: 16740769
-
Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.Bioconjug Chem. 2007 May-Jun;18(3):773-84. doi: 10.1021/bc060314x. Epub 2007 Mar 9. Bioconjug Chem. 2007. PMID: 17346030
Cited by
-
In vivo imaging of human malignant mesothelioma grown orthotopically in the peritoneal cavity of nude mice.J Cancer. 2011 Mar 1;2:123-31. doi: 10.7150/jca.2.123. J Cancer. 2011. PMID: 21479131 Free PMC article.
-
Antibody-Based Approaches to Target Pancreatic Tumours.Antibodies (Basel). 2022 Jul 12;11(3):47. doi: 10.3390/antib11030047. Antibodies (Basel). 2022. PMID: 35892707 Free PMC article. Review.
-
Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.Clin Cancer Drugs. 2016 Oct;3(2):76-86. doi: 10.2174/2212697X03666160218215744. Clin Cancer Drugs. 2016. PMID: 27853672 Free PMC article.
-
Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.Cancer Immunol Immunother. 2011 Nov;60(11):1509-27. doi: 10.1007/s00262-011-1103-6. Epub 2011 Sep 13. Cancer Immunol Immunother. 2011. PMID: 21913025 Free PMC article. Review.
-
Discovery of mesothelin and exploiting it as a target for immunotherapy.Cancer Res. 2014 Jun 1;74(11):2907-12. doi: 10.1158/0008-5472.CAN-14-0337. Epub 2014 May 13. Cancer Res. 2014. PMID: 24824231 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
